Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (291-300 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|March 4, 2026
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AMLJennifer Marvin-Peek, Hagop Kantarjian, Wei-Ying Jen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Blood|November 15, 2021
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosisAdi Zoref-Lorenz, Jun Murakami, Liron Hofstetter, et al.
Leukemia|April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Cancer|November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research ConsortiumElias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology|April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score AnalysisElias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Leukemia|November 17, 2024
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasmsIan M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Pageof 44

Showing results (291-300 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|March 4, 2026
Evaluating the Impact of Fewer Frontline Intensive Chemotherapy Plus Venetoclax Consolidation Cycles on Outcomes in AMLJennifer Marvin-Peek, Hagop Kantarjian, Wei-Ying Jen, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 25, 2024
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid LeukemiaJason Yeh, Oren Pasvolsky, Rima M Saliba, et al.
Cancer|May 29, 2024
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantationJayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, et al.
Blood|November 15, 2021
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosisAdi Zoref-Lorenz, Jun Murakami, Liron Hofstetter, et al.
Leukemia|April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemiaGuillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Cancer|November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research ConsortiumElias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology|April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score AnalysisElias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Leukemia|November 17, 2024
A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasmsIan M Bouligny, Guillermo Montalban-Bravo, Koji Sasaki, et al.
Pageof 44